Press & News

People are different and so is their cancer, patients should be treated individually.

Mangold Fondkommission AB published an Analyst Report on 2cureX

May 6, 2021

Press Releases

Copenhagen — May 6, 2021 — Mangold Fondkommission AB issued today an Equity Analyst Report on 2cureX (Insight.Mangold).

The report is available in both Swedish and English at 2cureX’s web-site (Analyst Coverage).

For more information:
Fernando Andreu, Chief Executive Officer
E-mail: fa@2curex.com
Telephone: +45 2279 5399
www.2curex.com

 Certified Adviser
Redeye AB
Phone: +46 8 121 576 90
Mail: certifiedadviser@redeye.se

About 2cureX
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D microtumors that functionally resemble the patient’s tumor and identifies the approved cancer treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient is given the selected treatment.

The first IndiTreat® product in metastatic colorectal cancer is introduced to the European market. Subsequent products help patients at different stages of colorectal cancer and other solid cancers.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: “2CUREX”). For more information about 2cureX visit www.2cureX.com.